Blood brain barrier disruption and glutamatergic excitotoxicity in post-acute sequelae of SARS COV-2 infection cognitive impairment: potential biomarkers and a window into pathogenesis.

BBB MRI PASC-CI diffusion tensor imaging glutamatergic excitotoxicity

Journal

Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899

Informations de publication

Date de publication:
2024
Historique:
received: 06 12 2023
accepted: 19 02 2024
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 17 5 2024
Statut: epublish

Résumé

To investigate the association between blood-brain barrier permeability, brain metabolites, microstructural integrity of the white matter, and cognitive impairment (CI) in post-acute sequelae of SARS-COV-2 infection (PASC). In this multimodal longitudinal MRI study 14 PASC participants with CI and 10 healthy controls were enrolled. All completed investigations at 3 months following acute infection (3 months ± 2 weeks SD), and 10 PASC participants completed at 12 months ± 2.22 SD weeks. The assessments included a standard neurological assessment, a cognitive screen using the brief CogState battery and multi-modal MRI derived metrics from Dynamic contrast enhanced (DCE) perfusion Imaging, Diffusion Tensor Imaging (DTI), and single voxel proton Magnetic Resonance Spectroscopy. These measures were compared between patients and controls and correlated with cognitive scores. At baseline, and relative to controls, PASC participants had higher K-Trans and Myo-inositol, and lower levels of Glutamate/Glutamine in the frontal white matter (FWM) ( PASC with CI is associated with BBB impairment, loss of WM integrity, and inflammation at 3 months which significantly but not uniformly improved at 12 months. The loss of WM integrity is possibly mediated by BBB impairment and associated glutamatergic excitotoxicity.

Identifiants

pubmed: 38756214
doi: 10.3389/fneur.2024.1350848
pmc: PMC11097901
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1350848

Informations de copyright

Copyright © 2024 Chaganti, Poudel, Cysique, Dore, Kelleher, Matthews, Darley, Byrne, Jakabek, Zhang, Lewis, Jha and Brew.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Joga Chaganti (J)

Thomas Jefferson University, Philadelphia, PA, United States.

Govinda Poudel (G)

Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, Australia.

Lucette Adeline Cysique (LA)

Department of Neurology and Immunology, Peter Duncan Neuroscience Unit, St Vincent's Hospital, University of New South Wales, Darlinghurst, NSW, Australia.

Gregory J Dore (GJ)

The Kirby Institute, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia.

Anthony Kelleher (A)

The Kirby Institute, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia.
St Vincent's Hospital, University of NSW, Darlinghurst, NSW, Australia.

Gael Matthews (G)

The Kirby Institute, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia.

David Darley (D)

Department of Neurology and Immunology, Peter Duncan Neuroscience Unit, St Vincent's Hospital, University of New South Wales, Darlinghurst, NSW, Australia.

Anthony Byrne (A)

St Vincent's Hospital, University of NSW, Darlinghurst, NSW, Australia.

David Jakabek (D)

St Vincent's Hospital, University of NSW, Darlinghurst, NSW, Australia.

Xin Zhang (X)

Royal Prince Alfred Hospital, Sydney, NSW, Australia.

Marrissa Lewis (M)

St Vincent's Hospital, University of NSW, Darlinghurst, NSW, Australia.

Nikhil Jha (N)

The Canberra Hospital, Canberra, ACT, Australia.

Bruce James Brew (BJ)

Department of Neurology and Immunology, Peter Duncan Neuroscience Unit, St Vincent's Hospital, University of New South Wales, Darlinghurst, NSW, Australia.
University of Notre Dame, Sydney, NSW, Australia.

Classifications MeSH